

Welcome to *Diagnostics and Therapeutics*: a new multidisciplinary forum for diseases diagnosis and treatment

Ding Qianshan^{1,2}

¹ Luminescence Press, Wuhan, Hubei 430000, P.R. China.

² Medical Research Center, Xi'an No. 3 Hospital, the Affiliated Hospital of Northwest University, Xi'an, Shaanxi 710016, P.R. China.

Correspondence: iamdqs@163.com

The history of human civilization is a history of struggles against disease. Today, for developing and underdeveloped countries, the lack of medical resources and medical technology limits the average life expectancy of residents and the quality of lives of patients. Infectious diseases including parasitic diseases are still dangerous killers for the population of these countries. While for developed countries, the incidence of cardiovascular and cerebrovascular diseases, diabetes and tumors caused by the aging of the population is increasing rapidly, which brings heavy social and economic burdens to families and countries. In recent years, COVID-19 pandemic has markedly changed our lifestyles, and millions of people have lost their family members, relatives and friends. Humans have been looking for more advanced and reliable diagnosis and treatment strategies to deal with diseases.

In 2021, I left clinical work and devoted myself to the launch of Luminescence journals. As the founder of Luminescence Press, I am delighted and honored to be the Co-editors-in-chief of *Diagnostics and Therapeutics* (DT), since it will enable me to participate in the odyssey of humans fighting diseases and pursue a better life in a different way. We hope to build an international and diversified editorial team and make DT a platform that can provide global surgeons, physicians and medical scientists with the latest information on diagnostics and therapeutics for life-changing and life-threatening diseases. We welcome

the manuscripts that share the cutting-edge knowledge of diagnostic procedures and techniques and also papers that report the experience and perspectives of clinical practice. This journal will mainly accept case reports, clinical trials, meta-analysis and reviews on disease diagnosis and treatment, and we also look forward to original articles that explore novel technologies of diseases diagnosis and treatment.

DT, as the same as other Luminescence journals, in addition to publishing in English, our professional editing team will also provide the readers with abstracts in Chinese, and the full text of some selected manuscripts will be published in both Chinese and English. We also welcome authors to provide us with abstract in their native languages after the article is accepted. Additionally, DT is an open access (OA) and peer-reviewed journal, and all published contents in DT can be freely available to read, download and share by authors, scientific communities and readers all over the world. We advocate and practice open science by publishing OA journals, which is also beneficial for authors to enlarge global visibility and explore wider collaboration.

With our sustained efforts and the support from the editorial board members, reviewers, authors and readers, DT will surely make great progress in the next few years and become an outstanding medical journal.

Received: Jan.15,2022; Accepted: Feb.22,2022; Published: Feb.25,2022

Copyright ©2022 Qianshan Ding.

DOI: <https://doi.org/10.55976/dt.120221541>

This is an open-access article distributed under a CC BY license (Creative Commons Attribution 4.0 International License)

<https://creativecommons.org/licenses/by/4.0/>